Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Accumulated Depreciation & Amortization (2016 - 2020)

Endonovo Therapeutics has reported Accumulated Depreciation & Amortization over the past 8 years, most recently at $88214.0 for Q4 2020.

  • Quarterly results put Accumulated Depreciation & Amortization at $88214.0 for Q4 2020, up 5.17% from a year ago — trailing twelve months through Dec 2020 was $88214.0 (up 5.17% YoY), and the annual figure for FY2020 was $88214.0, up 5.17%.
  • Accumulated Depreciation & Amortization for Q4 2020 was $88214.0 at Endonovo Therapeutics, up from $87311.0 in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for ENDV hit a ceiling of $88214.0 in Q4 2020 and a floor of $54492.0 in Q2 2016.
  • Median Accumulated Depreciation & Amortization over the past 4 years was $81646.5 (2019), compared with a mean of $79024.5.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: increased 4.23% in 2019 and later increased 5.28% in 2020.
  • Endonovo Therapeutics' Accumulated Depreciation & Amortization stood at $58451.0 in 2016, then soared by 37.68% to $80474.0 in 2018, then grew by 4.23% to $83879.0 in 2019, then grew by 5.17% to $88214.0 in 2020.
  • The last three reported values for Accumulated Depreciation & Amortization were $88214.0 (Q4 2020), $87311.0 (Q3 2020), and $86408.0 (Q2 2020) per Business Quant data.